Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Rumpl3StiltSkinon Dec 08, 2023 2:26pm
228 Views
Post# 35775378

RE:RE:RE:RE:RE:RE:RE:28 places in this most recent private placement

RE:RE:RE:RE:RE:RE:RE:28 places in this most recent private placement
Oilminerdeluxe wrote: That fast AA.approval we hope for. Wasn't it said that results had to be similar to the Phase 1 data? Like 67% CR? We are not there. Is it enough to be just better than the competition t be eligible for AA? 


It is true that the initial discussions TLT had with the FDA that 66% figure may have been used but only because that was what they saw in phase 1, with very few patients. Obviously a CR % ike that would be a no brainer for the FDA to give AA. One of the Dr. Ks, I forget which one, said that 30% CR would be a great %. I am guessing you are correct that we just need to be better than the current SoC to get AA. And in our case that is only for late stage NMIBC...
<< Previous
Bullboard Posts
Next >>